ANIXA BIOSCIENCES INC(NASDAQ:ANIX) stock Fundamental Analysis

Fundamental Rating

Overall ANIX gets a fundamental rating of 3 out of 10. We evaluated ANIX against 566 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANIX as it has an excellent financial health rating, but there are worries on the profitability. ANIX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ANIX had negative earnings in the past year.

ANIX had a negative operating cash flow in the past year.

In the past 5 years ANIX always reported negative net income.

In the past 5 years ANIX always reported negative operating cash flow.

1.2 Ratios

ANIX has a Return On Assets of -66.03%. This is in the lower half of the industry: ANIX underperforms 63.25% of its industry peers.

ANIX has a Return On Equity (-69.92%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-66.03%
ROE	-69.92%
ROIC	N/A

ROA(3y)-47.1%

ROA(5y)-56.61%

ROE(3y)-49.97%

ROE(5y)-60.17%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANIX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ANIX has more shares outstanding than it did 1 year ago.

ANIX has more shares outstanding than it did 5 years ago.

There is no outstanding debt for ANIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 31.76 indicates that ANIX is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 31.76, ANIX belongs to the top of the industry, outperforming 97.53% of the companies in the same industry.

There is no outstanding debt for ANIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	31.76

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ANIX has a Current Ratio of 9.35. This indicates that ANIX is financially healthy and has no problem in meeting its short term obligations.

ANIX has a Current ratio of 9.35. This is in the better half of the industry: ANIX outperforms 77.56% of its industry peers.

A Quick Ratio of 9.35 indicates that ANIX has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 9.35, ANIX is in the better half of the industry, outperforming 77.56% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	9.35
Quick Ratio	9.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ANIX have decreased strongly by -14.71% in the last year.

The Revenue for ANIX has decreased by -100.00% in the past year. This is quite bad

EPS 1Y (TTM)-14.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ANIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.88% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y4.98%

EPS Next 2Y3.3%

EPS Next 3Y3.56%

EPS Next 5Y33.88%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ANIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ANIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y3.3%

EPS Next 3Y3.56%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ANIX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ANIXA BIOSCIENCES INC

NASDAQ:ANIX (5/1/2025, 8:45:07 PM)

After market: 2.79 0 (0%)

2.79

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)03-11 2025-03-11/amc

Earnings (Next)N/A N/A

Inst Owners16.41%

Inst Owner Change0.27%

Ins Owners2.39%

Ins Owner Change4.46%

Market Cap89.84M

Analysts82.22

Price Target9.18 (229.03%)

Short Float %1.24%

Short Ratio5.15

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-0.92%

Min EPS beat(2)-3.81%

Max EPS beat(2)1.96%

EPS beat(4)2

Avg EPS beat(4)1.46%

Min EPS beat(4)-3.81%

Max EPS beat(4)10.87%

EPS beat(8)5

Avg EPS beat(8)6.5%

EPS beat(12)8

Avg EPS beat(12)11.47%

EPS beat(16)10

Avg EPS beat(16)3.24%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)5.88%

PT rev (3m)5.88%

EPS NQ rev (1m)0%

EPS NQ rev (3m)9.09%

EPS NY rev (1m)0%

EPS NY rev (3m)0.46%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	5.03
P/tB	5.03
EV/EBITDA	N/A

EPS(TTM)-0.39

EYN/A

EPS(NY)-0.36

Fwd EYN/A

FCF(TTM)-0.25

FCFYN/A

OCF(TTM)-0.25

OCFYN/A

SpS0

BVpS0.55

TBVpS0.55

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-66.03%
ROE	-69.92%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-47.1%

ROA(5y)-56.61%

ROE(3y)-49.97%

ROE(5y)-60.17%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	9.35
Quick Ratio	9.35
Altman-Z	31.76

F-Score2

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-14.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

EPS Next Y4.98%

EPS Next 2Y3.3%

EPS Next 3Y3.56%

EPS Next 5Y33.88%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-14.35%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-8.93%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-8.93%

OCF growth 3YN/A

OCF growth 5YN/A

ANIXA BIOSCIENCES INC (ANIX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens